Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Antiretroviral therapy may prevent some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

15 Mar 2005

New hepatitis drug wins approval by FDA

An experimental hepatitis B drug has earned the praise of US health experts for its effectiveness and has been recommended by the US Food and Drug Administration (FDA) advisory panel to treat the liver disease in adults.

14 Mar 2005

Diabetic patients run three times the risk of developing liver cancer

The researchers trawled a surveillance database used for patients in receipt of Medicare funding for health care, to identify patients aged 65 and older, who had been diagnosed with liver cancer.

7 Mar 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

2.5 million euros helps fight liver cancer

The overall project will concentrate on three areas where Europe is in a relatively favourable position compared with the US - human tissue resources, ribonucleic acid (RNA) technology, and structural proteomics. However, the initial focus will be on the development of genomics targets in hepatocellular carcinoma (HCC) or liver cancer as it is one of the leading causes of cancer death worldwide and has a very poor prognosis.

22 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005

Coffee consumption may be associated with a decreased risk of hepatocellular carcinoma

Two new studies in the February 16 issue of the Journal of the National Cancer Institute examine the effects of coffee consumption on the incidence of liver and colorectal cancers. One study found that drinking coffee daily is associated with a decreased risk of liver cancer, while the other found no association between drinking coffee or tea and the risk of colorectal cancer.

15 Feb 2005

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Consumption of alcohol the risk of several common cancers

An article appearing in the Journal of Thrombosis and Haemostasis presents definite evidence of these findings amongst other papers as part of an open forum discussion on wine, alcohol, and cardiovascular risk.

19 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

New hope for millions of patients suffering from liver damage (cirrhosis)

Millions of patients suffering from liver damage (cirrhosis) and failure may benefit from research by the Universities of Edinburgh and Southampton which may lead to new life-saving treatments. There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

5 Jan 2005

Instead of chemotherapy, drugs that influence the X protein's behavior might become an alternative cancer therapy

Identifying the link between chronic hepatitis B infection and liver cancer may one day help cancer patients sidestep the poison of chemotherapy, a Purdue University study suggests.

13 Dec 2004

Cryotherapy and MRI shows tumors freezing in real time

Cryotherapy combined with magnetic resonance imaging (MRI) is giving doctors unprecedented control during liver cancer treatment by allowing them to observe the tumors freezing in real time, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2004

Eating apples may protect against Alzheimer's and Parkinsonism

A group of chemicals in apples could protect the brain from the type of damage that triggers such neurodegenerative diseases as Alzheimer's and Parkinsonism, according to two new studies from Cornell University food scientists.

18 Nov 2004

Britain should adopt universal hepatitis B immunisation

The United Kingdom is one of the few developed countries that have not implemented universal immunisation. Because the burden of hepatitis B was low and individual rights were considered paramount, a policy of selective immunisation of high-risk groups, such as health care workers, homosexual men, and drug addicts, has been followed.

5 Nov 2004